Coeptis Therapeutics Stock Probability of Future Stock Price Finishing Under 0.67

COEP Stock  USD 0.17  0.01  4.44%   
Coeptis Therapeutics' future price is the expected price of Coeptis Therapeutics instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of Coeptis Therapeutics performance during a given time horizon utilizing its historical volatility. Check out Coeptis Therapeutics Backtesting, Coeptis Therapeutics Valuation, Coeptis Therapeutics Correlation, Coeptis Therapeutics Hype Analysis, Coeptis Therapeutics Volatility, Coeptis Therapeutics History as well as Coeptis Therapeutics Performance.
To learn how to invest in Coeptis Stock, please use our How to Invest in Coeptis Therapeutics guide.
  
At this time, Coeptis Therapeutics' Price To Sales Ratio is relatively stable compared to the past year. As of 12/11/2024, Price Earnings To Growth Ratio is likely to grow to 0.01, while Price To Operating Cash Flows Ratio is likely to drop (2.92). Please specify Coeptis Therapeutics' target price for which you would like Coeptis Therapeutics odds to be computed.

Coeptis Therapeutics Target Price Odds to finish below 0.67

The tendency of Coeptis Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to stay under $ 0.67  after 90 days
 0.17 90 days 0.67 
close to 99
Based on a normal probability distribution, the odds of Coeptis Therapeutics to stay under $ 0.67  after 90 days from now is close to 99 (This Coeptis Therapeutics probability density function shows the probability of Coeptis Stock to fall within a particular range of prices over 90 days) . Probability of Coeptis Therapeutics price to stay between its current price of $ 0.17  and $ 0.67  at the end of the 90-day period is about 88.59 .
Given the investment horizon of 90 days Coeptis Therapeutics has a beta of 0.65 suggesting as returns on the market go up, Coeptis Therapeutics average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Coeptis Therapeutics will be expected to be much smaller as well. Additionally Coeptis Therapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial.
   Coeptis Therapeutics Price Density   
       Price  

Predictive Modules for Coeptis Therapeutics

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Coeptis Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Coeptis Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
0.010.185.57
Details
Intrinsic
Valuation
LowRealHigh
0.051.006.39
Details
Naive
Forecast
LowNextHigh
00.185.57
Details
1 Analysts
Consensus
LowTargetHigh
3.193.503.89
Details

Coeptis Therapeutics Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Coeptis Therapeutics is not an exception. The market had few large corrections towards the Coeptis Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Coeptis Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Coeptis Therapeutics within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
-0.03
β
Beta against Dow Jones0.65
σ
Overall volatility
0.02
Ir
Information ratio -0.01

Coeptis Therapeutics Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Coeptis Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Coeptis Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Coeptis Therapeutics generated a negative expected return over the last 90 days
Coeptis Therapeutics has high historical volatility and very poor performance
Coeptis Therapeutics has some characteristics of a very speculative penny stock
Coeptis Therapeutics has a very high chance of going through financial distress in the upcoming years
Coeptis Therapeutics currently holds 1.71 M in liabilities with Debt to Equity (D/E) ratio of 1.89, which is about average as compared to similar companies. Coeptis Therapeutics has a current ratio of 0.55, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Coeptis Therapeutics' use of debt, we should always consider it together with its cash and equity.
Net Loss for the year was (37.57 M) with profit before overhead, payroll, taxes, and interest of 75 K.
Coeptis Therapeutics currently holds about 2.38 M in cash with (3.88 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.06.
Roughly 19.0% of Coeptis Therapeutics shares are held by company insiders
Latest headline from MacroaxisInsider: Acquisition by Christine Sheehy of 200000 shares of Coeptis Therapeutics at 1.6 subject to Rule 16b-3

Coeptis Therapeutics Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Coeptis Stock often depends not only on the future outlook of the current and potential Coeptis Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Coeptis Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding14.3 M
Cash And Short Term Investments3.8 M

Coeptis Therapeutics Technical Analysis

Coeptis Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Coeptis Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Coeptis Therapeutics. In general, you should focus on analyzing Coeptis Stock price patterns and their correlations with different microeconomic environments and drivers.

Coeptis Therapeutics Predictive Forecast Models

Coeptis Therapeutics' time-series forecasting models is one of many Coeptis Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Coeptis Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

Things to note about Coeptis Therapeutics

Checking the ongoing alerts about Coeptis Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Coeptis Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Coeptis Therapeutics generated a negative expected return over the last 90 days
Coeptis Therapeutics has high historical volatility and very poor performance
Coeptis Therapeutics has some characteristics of a very speculative penny stock
Coeptis Therapeutics has a very high chance of going through financial distress in the upcoming years
Coeptis Therapeutics currently holds 1.71 M in liabilities with Debt to Equity (D/E) ratio of 1.89, which is about average as compared to similar companies. Coeptis Therapeutics has a current ratio of 0.55, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Coeptis Therapeutics' use of debt, we should always consider it together with its cash and equity.
Net Loss for the year was (37.57 M) with profit before overhead, payroll, taxes, and interest of 75 K.
Coeptis Therapeutics currently holds about 2.38 M in cash with (3.88 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.06.
Roughly 19.0% of Coeptis Therapeutics shares are held by company insiders
Latest headline from MacroaxisInsider: Acquisition by Christine Sheehy of 200000 shares of Coeptis Therapeutics at 1.6 subject to Rule 16b-3

Additional Tools for Coeptis Stock Analysis

When running Coeptis Therapeutics' price analysis, check to measure Coeptis Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Coeptis Therapeutics is operating at the current time. Most of Coeptis Therapeutics' value examination focuses on studying past and present price action to predict the probability of Coeptis Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Coeptis Therapeutics' price. Additionally, you may evaluate how the addition of Coeptis Therapeutics to your portfolios can decrease your overall portfolio volatility.